Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Viridian Therapeutics, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
VRDN
Nasdaq
2830
www.viridiantherapeutics.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Viridian Therapeutics, Inc.
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Feb 6th, 2025 9:01 pm
Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease
- Jan 8th, 2025 12:00 pm
Is Viridian Therapeutics, Inc. (NASDAQ:VRDN) Worth US$19.3 Based On Its Intrinsic Value?
- Dec 25th, 2024 11:35 am
Viridian Therapeutics announces THRIVE-2 trial met primary, secondary endpoints
- Dec 17th, 2024 12:40 pm
Viridian Stock Flashes A Bullish Sign In Its Eye-Disease Battle With Amgen
- Dec 16th, 2024 9:09 pm
Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease
- Dec 16th, 2024 12:00 pm
Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024
- Dec 13th, 2024 11:00 pm
Viridian Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
- Nov 14th, 2024 10:10 am
Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data
- Nov 12th, 2024 12:00 pm
Viridian Therapeutics Insiders Added US$616.3k Of Stock To Their Holdings
- Oct 31st, 2024 12:38 pm
Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock
- Sep 12th, 2024 3:25 am
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
- Sep 10th, 2024 8:01 pm
Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease
- Sep 10th, 2024 11:00 am
Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024
- Sep 9th, 2024 8:01 pm
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results
- Aug 8th, 2024 12:15 pm
Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)
- Jul 25th, 2024 12:00 pm
Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease
- Jun 11th, 2024 10:00 am
Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences
- May 31st, 2024 12:00 pm
Viridian Therapeutics to Participate in Upcoming May Investor Conferences
- May 10th, 2024 12:00 pm
Viridian Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
- May 9th, 2024 10:56 am
Scroll